

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)



(10) International Publication Number
WO 2022/187622 A1

(51) International Patent Classification:

A61K 31/7088 (2006.01) C12N 15/11 (2006.01)
A61K 31/7105 (2006.01) C12N 15/113 (2010.01)
A61K 31/711 (2006.01) C12N 15/12 (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:

PCT/US2022/018911

(22) International Filing Date:

04 March 2022 (04.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/157,465 05 March 2021 (05.03.2021) US
63/214,153 23 June 2021 (23.06.2021) US

(71) Applicant: **DICERNA PHARMACEUTICALS, INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: **GANESH, Shanthi**; 75 Hayden Avenue, Lex-
ington, Massachusetts 02421 (US). **ABRAMS, Marc**; 75
Hayden Avenue, Lexington, Massachusetts 02421 (US).

DUDEK, Henryk T.; 75 Hayden Avenue, Lexington,
Massachusetts 02421 (US). **KRISHNAN, Harini Sivagu-**
runatha; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(74) Agent: **MANDRAGOURAS, Amy** et al.; Cooley LLP,
1299 Pennsylvania Ave., NW Suite 700, Washington, Dis-
trict of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: RNAI CONJUGATES AND USES THEREOF




FIG. 1A

B = any nucleobase

(57) Abstract: The subject matter disclosed herein is directed to modulating gene expression using siRNA compositions and methods directed to affecting key cell populations supporting the growth and metastasis of cancer to affect the beneficial treatment, remission or removal of the underlying tumor in a patient.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*